Children's Hospital Colorado

Q: Advances and Answers in Pediatric Health

By prioritizing and advancing research, education, clinical work and process improvement, we're speeding the integration of our discoveries into the clinical engine, helping patients in new and innovative ways. A unique and strong partnership with University of Colorado Anschutz Medical Campus provides fresh perspectives and invaluable expertise, as do our relationships with national and international research consortiums, industry partners and other children's hospitals.

It starts with a Q:

Like the kids we treat at Children's Hospital Colorado, we're creating a culture that continuously inspires curiosity. Doing so unlocks a new realm of pediatrics — one that swaps insular science and medicine for collaborative, progressive approaches to accelerating discovery.

Questions once asked within the silos of specific specialties are more and more commonly being addressed across multidisciplinary planes. These approaches are producing remarkable advances because here, we imagine the future and simultaneously create it.

Read the latest articles from our current issue of Q: and find all past issues below.

Validating vaccines

The percentage of parents who refuse all vaccines for their children is small, roughly 3%. There is, however, an increasing number of parents who refuse or want to defer individual vaccines or use an immunization schedule that isn’t recommended. Dr. Allison Kempe and Dr. Sean O’Leary have been researching vaccine hesitancy for over two decades. They are using their research to educate parents and inform providers on how to tackle this challenge.

Q: What’s the most effective way to increase public confidence in vaccines?

A syringe
Dr. Cost speaking with a patient.

Keep in training

Dr. Nicholas Cost is one of the nation’s few physicians who is fellowship trained as both a pediatric urologist and urologic oncologist. He was recently appointed Surgical Discipline Lead of the Children’s Oncology Group’s (COG) Renal Tumor Committee. Now, Dr. Cost and the COG committee are working to bolster surgeons’ confidence in treating rare renal tumors by regularly underscoring standards of care and sharing knowledge.

Q: When you’re the best at what you do, how do you leverage your expertise to help patients you don’t directly care for?

Nick Behrendt image centered

Case study: upside-down ablation

The best solution to TTTS is typically fetoscopic laser photocoagulation – a procedure that works well for placentas that implant on the posterior wall of the uterus and can even be used for anterior placentas. When the placenta covers the entire anterior uterine wall and then some, though, that’s a challenge. To address this unique case of TTTS, a team of our fetal surgeons put their heads together to develop an innovative surgical approach.

Q: How do you perform a minimally invasive fetoscopic laser ablation for TTTS when the placenta covers the entire anterior uterine wall?

Dr. Verneris working in a lab

Beyond the fringe

A built-in component of the innate immune system, natural killer cells are aptly named: They kill cancer. Dr. Michael Verneris was intrigued enough by that property to focus on studying them, and they’ve led him in some unexpected directions. Most recently, he’s been investigating the role of innate lymphoid cells in an astonishing array of diseases. Now, he, a hematology-oncology fellow and a pediatric gastroenterologist are exploring how they might be used to treat Crohn’s disease.

Q: What role do innate lymphoid cells play in conditions like Crohn’s disease, and could bone marrow transplant help?

Recent issues of Q:

Read previous issues of Q: to learn how our clinicians work together and across specialties to continually improve patient care and outcomes.

Past Issues of Q:

Stay informed